KALA BIO announced that Todd Bazemore has been named President and Chief Executive Officer, CEO, of KALA BIO and appointed to the Board of Directors. Bazemore has served as KALA’s interim CEO since February 2025 and previously served as KALA’s President and Chief Operating Officer, COO.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KALA:
- Optimistic Buy Rating for Kala Pharmaceuticals Driven by KPI-012 Trial Prospects and Financial Viability
- Kala Pharmaceuticals Reports Q2 2025 Financial Results
- Kala Pharmaceuticals reports Q2 EPS ($1.71) vs ($3.16)
- Kala Pharmaceuticals initiated with a Buy at Ladenburg
- Promising Developments and Market Potential for Kala Pharmaceuticals’ KPI-012 Amidst Clinical and Regulatory Challenges